- Home
- ZEO vs DTIL Comparison
ZEO vs DTIL Comparison
Compare ZEO & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- DTIL
- Stock Information
- Founded
- ZEO 2005
- DTIL 2006
- Country
- ZEO United States
- DTIL United States
- Employees
- ZEO N/A
- DTIL N/A
- Industry
- ZEO
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- DTIL Health Care
- Exchange
- ZEO NYSE
- DTIL Nasdaq
- Market Cap
- ZEO 47.6M
- DTIL 44.1M
- IPO Year
- ZEO N/A
- DTIL 2019
- Fundamental
- Price
- ZEO $3.30
- DTIL $4.96
- Analyst Decision
- ZEO
- DTIL Strong Buy
- Analyst Count
- ZEO 0
- DTIL 3
- Target Price
- ZEO N/A
- DTIL $37.67
- AVG Volume (30 Days)
- ZEO 1.9M
- DTIL 1.3M
- Earning Date
- ZEO 01-28-2025
- DTIL 11-04-2024
- Dividend Yield
- ZEO N/A
- DTIL N/A
- EPS Growth
- ZEO N/A
- DTIL N/A
- EPS
- ZEO 0.67
- DTIL 1.45
- Revenue
- ZEO $95,455,763.00
- DTIL $75,096,000.00
- Revenue This Year
- ZEO N/A
- DTIL $52.95
- Revenue Next Year
- ZEO N/A
- DTIL N/A
- P/E Ratio
- ZEO $4.95
- DTIL $2.57
- Revenue Growth
- ZEO N/A
- DTIL 43.62
- 52 Week Low
- ZEO $1.05
- DTIL $3.61
- 52 Week High
- ZEO $11.60
- DTIL $19.43
- Technical
- Relative Strength Index (RSI)
- ZEO 61.46
- DTIL 46.54
- Support Level
- ZEO $1.98
- DTIL $5.10
- Resistance Level
- ZEO $3.95
- DTIL $7.44
- Average True Range (ATR)
- ZEO 0.60
- DTIL 0.66
- MACD
- ZEO -0.02
- DTIL 0.14
- Stochastic Oscillator
- ZEO 67.01
- DTIL 35.25
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.